Does the media favor LGND or MGTX?

In the previous week, Ligand Pharmaceuticals had 3 more articles in the media than MeiraGTx. MarketBeat recorded 5 mentions for Ligand Pharmaceuticals and 2 mentions for MeiraGTx. Ligand Pharmaceuticals' average media sentiment score of 1.35 beat MeiraGTx's score of 0.93 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MeiraGTx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, GRFS or MGTX?

Grifols has higher revenue and earnings than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grifols $8.51B 0.61 $454.82M $0.19 40.47 MeiraGTx $397.50M 3.34 -$114.20M $0.71 19.46

Is GRFS or MGTX more profitable?

MeiraGTx has a net margin of 19.87% compared to Grifols' net margin of 5.54%. MeiraGTx's return on equity of 283.85% beat Grifols' return on equity. Company Net Margins Return on Equity Return on Assets Grifols 5.54% 6.21% 2.39% MeiraGTx 19.87% 283.85% 29.39%

Does the media favor GRFS or MGTX?

In the previous week, Grifols had 1 more articles in the media than MeiraGTx. MarketBeat recorded 3 mentions for Grifols and 2 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 0.93 beat Grifols' score of 0.88 indicating that MeiraGTx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MeiraGTx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MGTX or ACAD?

In the previous week, ACADIA Pharmaceuticals had 13 more articles in the media than MeiraGTx. MarketBeat recorded 15 mentions for ACADIA Pharmaceuticals and 2 mentions for MeiraGTx. ACADIA Pharmaceuticals' average media sentiment score of 1.16 beat MeiraGTx's score of 0.93 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ACADIA Pharmaceuticals 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DYN or MGTX?

In the previous week, Dyne Therapeutics had 7 more articles in the media than MeiraGTx. MarketBeat recorded 9 mentions for Dyne Therapeutics and 2 mentions for MeiraGTx. Dyne Therapeutics' average media sentiment score of 1.76 beat MeiraGTx's score of 0.93 indicating that Dyne Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive MeiraGTx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer EWTX or MGTX?

In the previous week, Edgewise Therapeutics had 8 more articles in the media than MeiraGTx. MarketBeat recorded 10 mentions for Edgewise Therapeutics and 2 mentions for MeiraGTx. Edgewise Therapeutics' average media sentiment score of 1.59 beat MeiraGTx's score of 0.93 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive MeiraGTx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

MeiraGTx (MGTX) Competitors

$13.82 -0.32 (-2.26%)

As of 08/28/2026 04:00 PM Eastern

Compare

MGTX vs. LGND, GRFS, ACAD, DYN, and EWTX

Should you buy MeiraGTx stock or one of its competitors? MeiraGTx's main competitors and comparable companies include Ligand Pharmaceuticals (LGND), Grifols (GRFS), ACADIA Pharmaceuticals (ACAD), Dyne Therapeutics (DYN), and Edgewise Therapeutics (EWTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does MeiraGTx compare to Ligand Pharmaceuticals?

Ligand Pharmaceuticals (NASDAQ:LGND) and MeiraGTx (NASDAQ:MGTX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

Ligand Pharmaceuticals has higher earnings, but lower revenue than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$268.09M	20.86	$124.45M	$9.35	30.00
MeiraGTx	$397.50M	3.34	-$114.20M	$0.71	19.46

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.5% of MeiraGTx shares are owned by institutional investors. 5.6% of Ligand Pharmaceuticals shares are owned by company insiders. Comparatively, 7.4% of MeiraGTx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Ligand Pharmaceuticals has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market.

In the previous week, Ligand Pharmaceuticals had 3 more articles in the media than MeiraGTx. MarketBeat recorded 5 mentions for Ligand Pharmaceuticals and 2 mentions for MeiraGTx. Ligand Pharmaceuticals' average media sentiment score of 1.35 beat MeiraGTx's score of 0.93 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MeiraGTx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ligand Pharmaceuticals has a net margin of 67.88% compared to MeiraGTx's net margin of 19.87%. MeiraGTx's return on equity of 283.85% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	67.88%	20.06%	11.68%
MeiraGTx	19.87%	283.85%	29.39%

Ligand Pharmaceuticals currently has a consensus price target of $335.75, indicating a potential upside of 19.70%. MeiraGTx has a consensus price target of $26.17, indicating a potential upside of 89.34%. Given MeiraGTx's higher probable upside, analysts plainly believe MeiraGTx is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00
MeiraGTx	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Ligand Pharmaceuticals beats MeiraGTx on 9 of the 16 factors compared between the two stocks.

How does MeiraGTx compare to Grifols?

Grifols (NASDAQ:GRFS) and MeiraGTx (NASDAQ:MGTX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

67.5% of MeiraGTx shares are held by institutional investors. 0.2% of Grifols shares are held by insiders. Comparatively, 7.4% of MeiraGTx shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Grifols has higher revenue and earnings than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.61	$454.82M	$0.19	40.47
MeiraGTx	$397.50M	3.34	-$114.20M	$0.71	19.46

Grifols currently has a consensus target price of $10.00, indicating a potential upside of 30.04%. MeiraGTx has a consensus target price of $26.17, indicating a potential upside of 89.34%. Given MeiraGTx's stronger consensus rating and higher probable upside, analysts plainly believe MeiraGTx is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
MeiraGTx	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00

Grifols has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market.

In the previous week, Grifols had 1 more articles in the media than MeiraGTx. MarketBeat recorded 3 mentions for Grifols and 2 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 0.93 beat Grifols' score of 0.88 indicating that MeiraGTx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grifols	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MeiraGTx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MeiraGTx has a net margin of 19.87% compared to Grifols' net margin of 5.54%. MeiraGTx's return on equity of 283.85% beat Grifols' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
MeiraGTx	19.87%	283.85%	29.39%

Summary

MeiraGTx beats Grifols on 13 of the 17 factors compared between the two stocks.

How does MeiraGTx compare to ACADIA Pharmaceuticals?

MeiraGTx (NASDAQ:MGTX) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

MeiraGTx has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market.

In the previous week, ACADIA Pharmaceuticals had 13 more articles in the media than MeiraGTx. MarketBeat recorded 15 mentions for ACADIA Pharmaceuticals and 2 mentions for MeiraGTx. ACADIA Pharmaceuticals' average media sentiment score of 1.16 beat MeiraGTx's score of 0.93 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	10 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ACADIA Pharmaceuticals has a net margin of 33.42% compared to MeiraGTx's net margin of 19.87%. MeiraGTx's return on equity of 283.85% beat ACADIA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	19.87%	283.85%	29.39%
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%

ACADIA Pharmaceuticals has higher revenue and earnings than MeiraGTx. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$397.50M	3.34	-$114.20M	$0.71	19.46
ACADIA Pharmaceuticals	$1.07B	4.68	$391M	$2.22	13.11

MeiraGTx presently has a consensus target price of $26.17, suggesting a potential upside of 89.34%. ACADIA Pharmaceuticals has a consensus target price of $34.36, suggesting a potential upside of 18.04%. Given MeiraGTx's stronger consensus rating and higher probable upside, equities research analysts clearly believe MeiraGTx is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78

67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 7.4% of MeiraGTx shares are held by insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

ACADIA Pharmaceuticals beats MeiraGTx on 10 of the 17 factors compared between the two stocks.

How does MeiraGTx compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and MeiraGTx (NASDAQ:MGTX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

MeiraGTx has a net margin of 19.87% compared to Dyne Therapeutics' net margin of 0.00%. MeiraGTx's return on equity of 283.85% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-64.30%	-50.33%
MeiraGTx	19.87%	283.85%	29.39%

Dyne Therapeutics has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market.

96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 67.5% of MeiraGTx shares are owned by institutional investors. 9.5% of Dyne Therapeutics shares are owned by company insiders. Comparatively, 7.4% of MeiraGTx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Dyne Therapeutics presently has a consensus price target of $34.42, indicating a potential upside of 37.28%. MeiraGTx has a consensus price target of $26.17, indicating a potential upside of 89.34%. Given MeiraGTx's stronger consensus rating and higher probable upside, analysts plainly believe MeiraGTx is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87
MeiraGTx	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00

MeiraGTx has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A
MeiraGTx	$397.50M	3.34	-$114.20M	$0.71	19.46

In the previous week, Dyne Therapeutics had 7 more articles in the media than MeiraGTx. MarketBeat recorded 9 mentions for Dyne Therapeutics and 2 mentions for MeiraGTx. Dyne Therapeutics' average media sentiment score of 1.76 beat MeiraGTx's score of 0.93 indicating that Dyne Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
MeiraGTx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MeiraGTx beats Dyne Therapeutics on 10 of the 15 factors compared between the two stocks.

How does MeiraGTx compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and MeiraGTx (NASDAQ:MGTX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation.

Edgewise Therapeutics has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market.

In the previous week, Edgewise Therapeutics had 8 more articles in the media than MeiraGTx. MarketBeat recorded 10 mentions for Edgewise Therapeutics and 2 mentions for MeiraGTx. Edgewise Therapeutics' average media sentiment score of 1.59 beat MeiraGTx's score of 0.93 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
MeiraGTx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MeiraGTx has a net margin of 19.87% compared to Edgewise Therapeutics' net margin of 0.00%. MeiraGTx's return on equity of 283.85% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
MeiraGTx	19.87%	283.85%	29.39%

67.5% of MeiraGTx shares are owned by institutional investors. 21.3% of Edgewise Therapeutics shares are owned by insiders. Comparatively, 7.4% of MeiraGTx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Edgewise Therapeutics presently has a consensus price target of $50.33, indicating a potential upside of 17.71%. MeiraGTx has a consensus price target of $26.17, indicating a potential upside of 89.34%. Given MeiraGTx's stronger consensus rating and higher probable upside, analysts plainly believe MeiraGTx is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
MeiraGTx	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00

MeiraGTx has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
MeiraGTx	$397.50M	3.34	-$114.20M	$0.71	19.46

Summary

MeiraGTx beats Edgewise Therapeutics on 12 of the 16 factors compared between the two stocks.

Get MeiraGTx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MGTX vs. The Competition

Export

Metric	MeiraGTx	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.33B	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	19.46	11.62	273.16	25.45
Price / Sales	3.34	1,295.87	605.06	76.64
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	6.14	16.53	12.98	6.14
Net Income	-$114.20M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-3.63%	-0.31%	0.13%	-0.80%
1 Month Performance	15.36%	9.80%	7.08%	4.13%
1 Year Performance	89.32%	55.66%	24.67%	15.17%

MeiraGTx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MGTX MeiraGTx	3.9585 of 5 stars	$13.82 -2.3%	$26.17 +89.3%	+89.3%	$1.33B	$397.50M	19.46	300
LGND Ligand Pharmaceuticals	4.1051 of 5 stars	$285.12 +1.8%	$335.75 +17.8%	+73.5%	$5.68B	$290.54M	30.49	80	Positive News
GRFS Grifols	4.6671 of 5 stars	$8.01 +0.3%	$10.00 +24.8%	-22.9%	$5.45B	$8.51B	42.16	25,247
ACAD ACADIA Pharmaceuticals	4.6828 of 5 stars	$30.42 +2.6%	$34.25 +12.6%	+12.0%	$5.24B	$1.07B	13.70	510	Positive News Analyst Forecast
DYN Dyne Therapeutics	3.7073 of 5 stars	$26.36 +1.4%	$34.42 +30.6%	+85.8%	$4.93B	N/A	N/A	100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MGTX) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MeiraGTx (MGTX) Competitors

MGTX vs. LGND, GRFS, ACAD, DYN, and EWTX

How does MeiraGTx compare to Ligand Pharmaceuticals?

Summary

How does MeiraGTx compare to Grifols?

Summary

How does MeiraGTx compare to ACADIA Pharmaceuticals?

Summary

How does MeiraGTx compare to Dyne Therapeutics?

Summary

How does MeiraGTx compare to Edgewise Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGTX vs. The Competition

MeiraGTx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MeiraGTx (MGTX) Competitors

MGTX vs. LGND, GRFS, ACAD, DYN, and EWTX

How does MeiraGTx compare to Ligand Pharmaceuticals?

Which has better earnings and valuation, LGND or MGTX?

Do institutionals & insiders have more ownership in LGND or MGTX?

Which has more risk and volatility, LGND or MGTX?

Does the media favor LGND or MGTX?

Is LGND or MGTX more profitable?

Do analysts rate LGND or MGTX?

Summary

How does MeiraGTx compare to Grifols?

Do insiders & institutionals have more ownership in GRFS or MGTX?

Which has better valuation & earnings, GRFS or MGTX?

Do analysts recommend GRFS or MGTX?

Which has more risk and volatility, GRFS or MGTX?

Does the media favor GRFS or MGTX?

Is GRFS or MGTX more profitable?

Summary

How does MeiraGTx compare to ACADIA Pharmaceuticals?

Which has more risk and volatility, MGTX or ACAD?

Does the media refer more to MGTX or ACAD?

Is MGTX or ACAD more profitable?

Which has stronger valuation and earnings, MGTX or ACAD?

Do analysts rate MGTX or ACAD?

Do insiders and institutionals believe in MGTX or ACAD?

Summary

How does MeiraGTx compare to Dyne Therapeutics?

Is DYN or MGTX more profitable?

Which has more risk and volatility, DYN or MGTX?

Do institutionals and insiders have more ownership in DYN or MGTX?

Do analysts prefer DYN or MGTX?

Which has stronger valuation & earnings, DYN or MGTX?

Does the media favor DYN or MGTX?

Summary

How does MeiraGTx compare to Edgewise Therapeutics?

Which has more risk & volatility, EWTX or MGTX?

Does the media prefer EWTX or MGTX?

Is EWTX or MGTX more profitable?

Do institutionals & insiders believe in EWTX or MGTX?

Do analysts prefer EWTX or MGTX?

Which has stronger valuation & earnings, EWTX or MGTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGTX vs. The Competition

MeiraGTx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools